We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+14.5%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$59B
AUM Growth
+$9.67B
Cap. Flow
+$3.02B
Cap. Flow %
5.11%
Top 10 Hldgs %
26.45%
Holding
2,790
New
663
Increased
538
Reduced
776
Closed
680

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$905M
2
NVDA icon
NVIDIA
NVDA
+$592M
3
AMD icon
Advanced Micro Devices
AMD
+$439M
4
AMGN icon
Amgen
AMGN
+$385M
5
ADBE icon
Adobe
ADBE
+$382M

Sector Composition

Rank Sector Weight
1 Technology 14.79%
2 Consumer Discretionary 13.23%
3 Healthcare 12.61%
4 Financials 7.44%
5 Communication Services 6.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GPN icon
301
Global Payments
GPN
$22.1B
$37.1M 0.06%
291,864
-124,881
-30% -$14.5M
EXR icon
302
Extra Space Storage
EXR
$31.2B
$37.1M 0.06%
231,103
-300,218
-57% -$38.2M
ELF icon
303
e.l.f. Beauty
ELF
$4.56B
$37M 0.06%
256,013
+4,484
+2% +$517K
SBUX icon
304
PUT
Starbucks
SBUX
$118B
$36.9M 0.06%
+384,800
New +$37.5M
XLY icon
305
CALL
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$21.4B
$36.7M 0.06%
410,600
+326,200
+386% +$27M
AMZN icon
306
CALL
Amazon
AMZN
$2.5T
$36.7M 0.06%
241,400
+185,000
+328% +$25.9M
AMZN icon
307
PUT
Amazon
AMZN
$2.5T
$36.6M 0.06%
240,900
-67,700
-22% -$9.49M
HRL icon
308
Hormel Foods
HRL
$13.9B
$36.2M 0.06%
+1,128,273
New +$36.8M
PH icon
309
Parker-Hannifin
PH
$125B
$36M 0.06%
78,218
+37,755
+93% +$15.7M
CI icon
310
CALL
Cigna
CI
$76.6B
$35.9M 0.06%
+119,800
New +$35M
TFX icon
311
Teleflex
TFX
$5.85B
$35.8M 0.06%
143,612
+1,443
+1% +$308K
DNLI icon
312
Denali Therapeutics
DNLI
$3.67B
$35.8M 0.06%
+1,667,397
New +$33M
DD icon
313
DuPont de Nemours
DD
$18.6B
$35.8M 0.06%
+370,518
New +$33.7M
EWY icon
314
iShares MSCI South Korea ETF
EWY
$21.7B
$35.6M 0.06%
+543,180
New +$33M
VSTS icon
315
Vestis
VSTS
$2.06B
$35.3M 0.06%
+1,670,504
New +$28.7M
IMGN
316
DELISTED
Immunogen Inc
IMGN
$35.2M 0.06%
+1,187,027
New +$23.6M
TER icon
317
Teradyne
TER
$54.8B
$35.1M 0.06%
323,046
-37,339
-10% -$3.54M
RVMD icon
318
Revolution Medicines
RVMD
$40.2B
$34.7M 0.06%
1,208,929
+1,122,841
+1,304% +$27M
IR icon
319
Ingersoll Rand
IR
$33B
$34.4M 0.06%
444,565
-574,391
-56% -$39.3M
ICLR icon
320
Icon
ICLR
$12.8B
$34.4M 0.06%
121,422
-52,432
-30% -$13.6M
QGEN icon
321
Qiagen
QGEN
$8.53B
$34.2M 0.06%
741,721
-1,367,230
-65% -$58.2M
RDFN
322
DELISTED
Redfin
RDFN
$34M 0.06%
3,297,162
+2,490,874
+309% +$17.3M
TTD icon
323
Trade Desk
TTD
$8.13B
$33.7M 0.06%
+467,796
New +$34.4M
ROST icon
324
Ross Stores
ROST
$76.6B
$33.5M 0.06%
242,198
+219,637
+974% +$27.4M
WEX icon
325
WEX
WEX
$6.11B
$33.4M 0.06%
171,856
+72,023
+72% +$13.1M

Similar funds

Marshall Wace's Q4 2023 Portfolio in Review

As of Q4 2023, Marshall Wace held 2,790 positions worth $59B, up 20% from $49.4B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Marshall Wace deployed $3.02B of net new capital in Q4 2023, opening 663 new positions and adding to 538 existing holdings. Its largest new stake was Qualcomm: 1,674,985 shares worth $242M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Microsoft, an estimated $905M trimmed.

  • Marshall Wace's largest Q4 2023 buy was Qualcomm: 1,674,985 shares worth $242M.
  • Marshall Wace added most to iShares Core S&P 500 ETF in Q4 2023, an estimated $3.43B increase.
  • Marshall Wace's biggest Q4 2023 reduction was Microsoft, cutting an estimated $905M.
  • Marshall Wace fully exited VMware, Inc in Q4 2023, selling an estimated $149M.
  • Marshall Wace's ten largest holdings make up 26% of its $59B portfolio in Q4 2023.
  • Marshall Wace opened 663 new positions and closed 680 in Q4 2023.
  • Marshall Wace's portfolio value rose 20% quarter-over-quarter to $59B.

Based on Marshall Wace's 13F filing for Q4 2023, filed 14 Feb 2024.